MedTrace Logo

Pilot Study of COR-1 in Heart Failure

NCT01391507 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-10-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the effect of COR-1 in combination with standard therapy in patients with heart failure. The safety and tolerability of COR-1 will also be assessed.

Conditions

  • Cardiomyopathy, Dilated

Interventions

DRUG

0.9 % sodium chloride

Monthly intravenous injection for 6 months

DRUG

COR-1

Monthly intravenous injection for 6 months

DRUG

Standard therapy for heart failure

All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.

Sponsors & Collaborators

  • Corimmun GmbH

    lead INDUSTRY

Principal Investigators

  • Corimmun GmbH Clinical Trial · Corimmun GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01391507 on ClinicalTrials.gov